A detailed history of Stephens Consulting, LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 546 shares of MRNA stock, worth $63,920. This represents 0.02% of its overall portfolio holdings.

Number of Shares
546
Previous 500 9.2%
Holding current value
$63,920
Previous $49.7 Million 17.01%
% of portfolio
0.02%
Previous 0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 17, 2024

BUY
$85.37 - $115.44 $3,927 - $5,310
46 Added 9.2%
546 $58.2 Million
Q2 2023

Jul 20, 2023

SELL
$118.5 - $160.53 $59,250 - $80,265
-500 Reduced 50.0%
500 $60.8 Million
Q1 2023

Apr 19, 2023

SELL
$135.66 - $197.02 $271 - $394
-2 Reduced 0.2%
1,000 $154 Million
Q2 2022

Jan 19, 2023

SELL
$117.13 - $176.59 $6,207 - $9,359
-53 Reduced 5.02%
1,002 $143 Million
Q1 2022

Jan 19, 2023

SELL
$126.46 - $235.05 $64,115 - $119,170
-507 Reduced 32.46%
1,055 $182 Million
Q4 2021

Jan 19, 2023

BUY
$225.82 - $368.51 $352,730 - $575,612
1,562 New
1,562 $397 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $45.8B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Stephens Consulting, LLC Portfolio

Follow Stephens Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stephens Consulting, LLC with notifications on news.